News
ETON
3.140
-1.57%
-0.050
CVAC, SBNY and CRMD are among after hour movers
On the Move CVAC, SBNY and CRMD are among after hour movers. Vanda Pharmaceuticals and Sutro Biopharma are among the companies to gain. Eton Pharmaceuticals, Leslie's and Signature Bank are among those to lose. The day's top 10 stocks.
Seeking Alpha · 15h ago
Weekly Report: what happened at ETON last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ETON last week (0401-0405)?
Weekly Report · 04/08 11:31
Weekly Report: what happened at ETON last week (0325-0329)?
Weekly Report · 04/01 11:29
Weekly Report: what happened at ETON last week (0318-0322)?
Weekly Report · 03/25 11:32
Health Care Sector Update for 03/22/2024: ETON, OTLK, STVN, XLV, IBB
NASDAQ · 03/22 13:08
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Biolase (NASDAQ:BIOL) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. Eton Pharmaceuticals shares rose 15.46% during the day. Outlook Therapeutics and Nutriband also moved upwards. SINTX Techs shares declined by 34.0% in the pre- market.
Benzinga · 03/22 13:06
Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE
Healthcare Relief Therapeutics grants exclusive U.S. Rights to Eton Pharmaceuticals for PKU GOLIKE. Relief will receive an upfront payment of $2.2 million. Eton also receives rights to Relief's other rare metabolic diseases under development.
Seeking Alpha · 03/22 07:31
Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024
Benzinga · 03/22 06:29
Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics
NASDAQ · 03/22 06:22
Press Release: Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE(R) for Phenylketonuria
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE(R) for Phenylketonuria. PKU is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise. The company expects peak sales of more than $10 million annually in the U.S.
Dow Jones · 03/22 06:00
Press Release: Eton Pharmaceuticals Announces -2-
Discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. These and other risks concerning Eton's development programs and financial position are described in the company's filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date they are made.
Dow Jones · 03/22 06:00
Weekly Report: what happened at ETON last week (0311-0315)?
Weekly Report · 03/18 11:30
Geron, Graphite Bio, Immuneering among healthcare movers
Healthcare On the Move: Geron, Graphite Bio, Immuneering among healthcare movers. S&P 500 Health Care Sector -0.46% to 1688.46. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 03/15 14:00
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Eton Pharmaceuticals reported earnings per share of -9 cents for the fourth quarter of 2023. The company reported revenue of $7.31 million. This was 5.03% worse than the analyst estimate for revenue in the same period. Eton reported results for the last quarter of 2013.
Investorplace · 03/15 00:55
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/14 21:15
Recap: Eton Pharmaceuticals Q4 Earnings
Eton Pharmaceuticals reported its Q4 earnings on March 14. The company missed estimates by -125.0%. The company's revenue was down $1.19 million from the same period last year. Eton pharmaceuticals is expected to announce its earnings Thursday afternoon.
Benzinga · 03/14 20:20
*Eton Pharmaceuticals: Successful Results From ET-400's Pivotal Bioequivalence Study, NDA Submission Planned for 2Q
Dow Jones · 03/14 20:12
BRIEF-Eton Pharmaceuticals Q4 Net Income USD -2.256 Million
Reuters · 03/14 20:01
*Eton Pharmaceuticals 4Q Rev $7.31M >ETON
Dow Jones · 03/14 20:01
More
Webull provides a variety of real-time ETON stock news. You can receive the latest news about Eton Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.